Cover Image
市場調查報告書

全球肝疾病治療市場 - 機會及預測

World Liver Disease Treatment Market - Opportunities and Forecast, 2014 - 2022

出版商 Allied Market Research 商品編碼 367294
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球肝疾病治療市場 - 機會及預測 World Liver Disease Treatment Market - Opportunities and Forecast, 2014 - 2022
出版日期: 2016年07月01日 內容資訊: 英文 150 Pages
簡介

肝疾病治療市場,由於臨床的未滿足需求和預期今後的開發治療而預計成長。開發了對非酒精性脂肪肝病治療的維他命E和胰島素增敏劑等新的藥物。再加上肝癌症的發病率每年增加2.7%,這也成為帶動市場成長的要素。

本報告提供全球肝疾病治療市場相關調查,市場現狀及至2022年的預測,各治療,及各地區趨勢,參與企業簡介等彙整資料。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 調查結果
  • 波特五力分析
  • 市場佔有率分析
  • 促進要素
  • 阻礙要素
  • 機會

第4章 各治療市場

  • 簡介
  • 抗病毒藥物
  • 疫苗
  • 抗排斥藥物/免疫抑制劑
  • 化療藥物
  • 法律上的療法
  • 免疫球蛋白
  • 皮質類固醇

第5章 各地區市場

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美

第6章 企業簡介

  • Gilead Science Inc.
  • Bayer AG
  • AstraZeneca
  • GlaxoSmithKline plc
  • Merck & Co. Inc
  • Sanofi
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Johnson &Johnson Private Limited

圖表

目錄

Title: Liver Disease Treatment Market by Treatment Type (Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, IImmunoglobulins, Corticosteroids) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022.

Liver disease comprises of wide range of complex conditions affecting the liver. Liver disease treatment market is assured to grow on account of unmet clinical needs and upcoming treatment modifications. Number of novel agents has shown improvements in clinical trials such as obeticholic acid, thiazolidinediones and vitamin E for treatment of nonalcoholic fatty liver diseases. Additionally, according to American Cancer Society liver cancer rates increases 2.7% every year propelling the growth of market.

Changing lifestyle such as increasing consumption of alcohol, unhealthy diets have increased the incidences of liver disease. Whereas, growing geriatric population has lead to significant addition in the world liver disease treatment market. There is huge market potential for this market as the occurrences of disorders have become common. Government and non government awareness programs would help the growth of liver disease treatment Industry.

However, stringent government regulations (FDA, MHRA), high cost incurred in drug research and development pose a crucial challenge for liver disease treatment Industry. Side effect associated with medication is the growing concern expected for declining of market value. Patent expiry and growing health awareness in public would encourage the growth of the market. New research and development will provide immense opportunity for market players. For instance, Yaqrit Limited has developed a new product, Yaq-001 which will be introduced in 3 years for treatment of chronic liver diseases.

The liver disease treatment market is segmented into treatment type and geography. By treatment type the market is bifurcated into Chemotherapy drugs, targeted therapy, anti-viral drugs, immunoglobulins, corticosteroids, vaccines, anti-rejection drugs/immunosuppressant. By geography segmented into North America, Europe, APAC and LAMEA. North America is bifurcated into the U.S., Mexico and Canada whereas Europe have been further segmented into UK, Russia, Germany, Italy, France and rest of Europe. APAC comprises of China, India, Japan, South Korea, Taiwan and rest of Asia Pacific. LAMEA includes Latin America, Middle East and Africa.

WHO estimated increase in liver disease due to rising alcohol drinking in Europe whereas; more than 1000 people die of liver cancer due to aflatoxin in western pacific region. The major companies covered under the scope of the study are Gilead Science Inc., Bayer AG, AstraZeneca, GlaxoSmithKline plc, Merck & Co. Inc, Sanofi, Pfizer Inc., F. Hoffmann-La Roche AG, Novartis AG, and Johnson &Johnson Private Limited among others.

Changing lifestyle patterns such as increasing consumption of alcohol, unhealthy diets

Unhealthy diet, high stress levels and unorganized lifestyle patterns are the major driving forces of liver disease treatment market. Numbers of overweight and obesity in developed countries have quadrupled since 1980 thereby, escalating the risk of liver diseases. In addition, growing alcohol consumption has fueled rise in fatal liver disease. These drivers have increased incidences of liver diseases which would propel the growth of liver disease treatment market in future.

Increasing incidences of liver diseases

Increasing incidences of obesity, metabolic syndrome, diabetes and cardiovascular disorders that lead to liver diseases are another major factor boosting the growth of liver disease treatment market. Additionally, increasing prevalence of liver disease due to side effects of other drugs such as acetaminophen and poor hygienic and sanitation conditions are expected to drive the market in the coming years.

Growing geriatric population

Structural dysfunction or alteration due to aging mainly leads to liver diseases. According to the National Institute of Aging, geriatric population is likely to increase by 86% till 2050. The increasing rates of geriatric population have resulted in rise of the incidences of liver diseases, which further escalating the demand of liver disease treatment market.

Government and non government awareness program /Liver organizations

With increasing prevalence of liver diseases, increasing awareness has become a necessity. Government and not-for-profit organizations are playing a crucial role in the rising awareness about the liver diseases around the world. These organizations promote the awareness of the liver related diseases and support for research and development for the prevention, treatment and cure of liver diseases.

Increasing R&D to develop innovative products

Several companies are investing in their R&D to develop innovative and advanced treatment for liver disease. Research and development of high efficient and less or no side effects pharmaceutical drugs would drive the market in the near future.

Availability of generic and bio-similar drugs

Patent expiry in upcoming years of various block-buster liver disease treatment drugs have created new gateway for the entrance of generic market. Moreover, due to the low cost of generic drugs compared to the branded therapies, there is more preference towards generic drugs or bio similar drugs for the treatment of various diseases.

KEY BENEFITS FOR SHAREHOLDERS:

  • The report provides information regarding key drivers, restraints and opportunities with detailed analysis
  • The study provides an in-depth analysis of the fast food market with current and future trends to elucidate the imminent investment pockets in the liver disease treatment market
  • Current and future trends are outlined which will help new entrants and key players to gain a stronger foothold in the market
  • Quantitative analysis of the current market and estimations through 2014-2022 are provided to showcase the financial competency of the market
  • Porters Five Forces model of the industry illustrates the potency of the buyers & suppliers participating in the market
  • Comprehensive analyses of all geographical regions are presented that determines predominant opportunities in these geographies
  • Key market players of liver disease treatment are analyzed to understand the competitive outline of the world liver disease treatment market

KEY MARKET SEGMENTS:

By Treatment Type:

  • Anti-Rejection Drugs/Immunosupressants
  • Chemotherapy Drugs
  • Targeted therapy
  • Vaccines
  • Anti-Viral Drugs
  • Immunoglobulins
  • Corticosteroids

By Geography:

  • North America
    • U.S.
    • Mexico
    • Canada
  • Europe
    • UK
    • Russia
    • Germany
    • Italy
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Rest of Asia Pacific
  • LAMEA
    • Latin America
    • Middle East
    • Africa

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits
  • 1.3. Key market segments
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key Findings
    • 3.2.1. Top impacting factor
    • 3.2.2. Top winning strategies
    • 3.3.3. Top investment pockets
  • 3.3. Porters five forces analysis
    • 3.3.1. Low bargaining power of suppliers due to large number of suppliers and low switching cost
    • 3.3.2. Moderate bargaining power of buyer due to large number of buyer, high product dependency and less switching cost.
    • 3.3.3. Low threat of substitutes due to low preference of substitutes and high brand loyalty
    • 3.3.4. Low threat of new entrants due to presence of dominant players and strict government regulations
    • 3.3.5. Presence of numerous players, high exist barriers, high economic base increases the competition among rivalries
  • 3.4. Market share analysis, 2015
  • 3.5. Drivers
    • 3.5.1. Rapidly changing lifestyle patterns such as increasing consumption of alcohol, and unhealthy diets
    • 3.5.2. Increasing prevalence of liver diseases
    • 3.5.3. Growing geriatric population
    • 3.5.4. Increasing government and non-government awareness programs
    • 3.5.5. Increasing R&D investments for the development of novel therapies
  • 3.6. Restraint
    • 3.6.1. Stringent government regulations
    • 3.6.2. High cost incurred in drug R&D
    • 3.6.3. Side effect associated with medication
  • 3.7. Opportunities
    • 3.7.1. Availability of generic and bio-similar drugs

CHAPTER 4: WORLD LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE

  • 4.1. Introduction
  • 4.2. Anti viral drugs
    • 4.2.1. Key market trends
    • 4.2.2. Key growth factors and opportunities
    • 4.2.3. Market size and forecast
    • 4.2.4. North America antiviral drugs market
    • 4.2.5. Europe antiviral drugs market
    • 4.2.6. Asia Pacific antiviral drugs market
    • 4.2.7. LAMEA antiviral drugs market
  • 4.3. Vaccines
    • 4.3.1. Key market trends
    • 4.3.2. Key growth factors and opportunities
    • 4.3.3. Market size and forecast
    • 4.3.4. North America vaccines market
    • 4.3.5. Europe vaccines market
    • 4.3.6. Asia Pacific vaccines market
    • 4.3.7. LAMEA vaccines market
  • 4.4. Anti rejection drugs/ immunosuppressant drugs
    • 4.4.1. Key market trends
    • 4.4.2. Key growth factors and opportunities
    • 4.4.3. Market size and forecast
    • 4.4.4. North America anti rejection drugs / immunosuppresant drugs market
    • 4.4.5. Europe anti rejection drugs / immunosuppresant drugs market
    • 4.4.6. Asia Pacific anti rejection drugs / immunosuppresant drugs market
    • 4.4.7. LAMEA anti rejection drugs / immunosuppresant drugs market
  • 4.5. Chemotherapy drugs
    • 4.5.1. Key market trends
    • 4.5.2. Key growth factors and opportunities
    • 4.5.3. Market size and forecast
    • 4.5.4. North America chemotherapy drugs market
    • 4.5.5. Europe chemotherapy drugs market
    • 4.5.6. Asia Pacific chemotherapy drugs market
    • 4.5.7. LAMEA chemotherapy drugs market
  • 4.6. Targeted therapy
    • 4.6.1. Key market trends
    • 4.6.2. Key growth factors and opportunities
    • 4.6.3. Market size and forecast
    • 4.6.4. North America targeted therapy market
    • 4.6.5. Europe targeted therapy market
    • 4.6.6. Asia Pacific targeted therapy market
    • 4.6.7. LAMEA targeted therapy market
  • 4.7. Immunoglobulin
    • 4.7.1. Key market trends
    • 4.7.2. Key growth factors and opportunities
    • 4.7.3. Market size and forecast
    • 4.7.4. North America immunoglobulin market
    • 4.7.5. Europe immunoglobulin market
    • 4.7.6. Asia Pacific immunoglobulin market
    • 4.7.7. LAMEA immunoglobulin market
  • 4.8. Corticosteroids
    • 4.8.1. Key market trends
    • 4.8.2. Key growth factors and opportunities
    • 4.8.3. Market size and forecast
    • 4.8.4. North America corticosteroids market
    • 4.8.5. Europe corticosteroids market
    • 4.8.6. Asia Pacific corticosteroids market
    • 4.8.7. LAMEA corticosteroids market

CHAPTER 5: WORLD LIVER DISEASE TREATMENT MARKET, BY GEOGRAPHY

  • 5.1. Introduction
  • 5.2. North America
    • 5.2.1. Key market trends
    • 5.2.2. Key growth factors and opportunities
    • 5.2.3. Market size and forecast
    • 5.2.4. U.S. liver disease treatment market
    • 5.2.5. Mexico liver disease treatment market
    • 5.2.6. Canada liver disease treatment market
  • 5.3. Europe
    • 5.3.1. Key market trends
    • 5.3.2. Key growth factors and opportunities
    • 5.3.3. Market size and forecast
    • 5.3.4. Germany liver disease treatment market
    • 5.3.5. UK liver disease treatment market
    • 5.3.6. Italy liver disease treatment market
    • 5.3.7. France liver disease treatment market
    • 5.3.8. Rest of Europe liver disease treatment market
  • 5.4. Asia Pacific (APAC)
    • 5.4.1. Key market trends
    • 5.4.2. Key growth factors and opportunities
    • 5.4.3. Market size and forecast
    • 5.4.4. Japan liver disease treatment market
    • 5.4.5. China liver disease treatment market
    • 5.4.6. India liver disease treatment market
    • 5.4.7. Rest of APAC liver disease treatment market
  • 5.5. LAMEA
    • 5.5.1. Key market trends
    • 5.5.2. Key growth factors and opportunities
    • 5.5.3. Market size and forecast
    • 5.5.4. Latin America liver disease treatment market
    • 5.5.5. Middle East liver disease treatment market
    • 5.5.6. Africa liver disease treatment market

CHAPTER 7: COMPANY PROFILES

  • 7.1. Gilead Science Inc.
    • 7.1.1. Company overview
    • 7.1.2. Company snapshot
    • 7.1.3. Operating business segment overview
    • 7.1.4. Business performance
    • 7.1.5. Strategic moves and developments
  • 7.2. Bayer AG
    • 7.2.1. Company overview
    • 7.2.2. Company snapshot
    • 7.2.3. Operating business segment overview
    • 7.2.4. Business performance
    • 7.2.5. Strategic moves and developments
  • 7.3. AstraZeneca
    • 7.3.1. Company overview
    • 7.3.2. Company snapshot
    • 7.3.3. Operating business segment overview
    • 7.3.4. Business performance
    • 7.3.5. Strategic moves and developments
  • 7.4. GlaxoSmithKline plc
    • 7.4.1. Company overview
    • 7.4.2. Company snapshot
    • 7.4.3. Operating business segment overview
    • 7.4.4. Business performance
    • 7.4.5. Strategic moves and developments
  • 7.5. Merck & Co. Inc
    • 7.5.1. Company overview
    • 7.5.2. Company snapshot
    • 7.5.3. Operating business segment overview
    • 7.5.4. Business performance
    • 7.5.5. Strategic moves and developments
  • 7.6. Sanofi
    • 7.6.1. Company overview
    • 7.6.2. Company snapshot
    • 7.6.3. Operating business segment overview
    • 7.6.4. Business performance
    • 7.6.5. Strategic moves and developments
  • 7.7. Pfizer Inc.
    • 7.7.1. Company overview
    • 7.7.2. Company snapshot
    • 7.7.3. Operating business segment overview
    • 7.7.4. Business performance
    • 7.7.5. Strategic moves and developments
  • 7.8. F. Hoffmann-La Roche AG
    • 7.8.1. Company overview
    • 7.8.2. Company snapshot
    • 7.8.3. Operating business segment overview
    • 7.8.4. Business performance
    • 7.8.5. Strategic moves and developments
  • 7.9. Novartis AG
    • 7.9.1. Company overview
    • 7.9.2. Company snapshot
    • 7.9.3. Operating business segment overview
    • 7.9.4. Business performance
    • 7.9.5. Strategic moves and developments
  • 7.10. Johnson &Johnson Private Limited
    • 7.10.1. Company overview
    • 7.10.2. Company snapshot
    • 7.10.3. Operating business segment overview
    • 7.10.4. Business performance
    • 7.10.5. Strategic moves and developments

List of Tables

  • TABLE 1: MAJOR REGULATORY AUTHORITY WORLD WIDE
  • TABLE 2: CLINICAL TRAILS ONGOING ON DIFFERENT LIVER DISEASES
  • TABLE 3: WORLD ANTIVIRAL DRUGS MARKET, ($MILLION), GROWTH (%)2014-2022
  • TABLE 4: NORTH AMERICA ANTIVIRAL DRUGS MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 5: EUROPE ANTIVIRAL DRUGS MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 6: ASIA PACIFIC ANTIVIRAL DRUGS MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 7: LAMEA ANTIVIRAL DRUGS MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 8: WORLD VACCINES MARKET, ($MILLION), GROWTH (%)2014-2022
  • TABLE 9: NORTH AMERICA VACCINES MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 10: EUROPE VACCINES MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 11: ASIA PACIFIC VACCINES MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 12: LAMEA VACCINES MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 13: WORLD ANTI REJECTION DRUGS / IMMUNOSUPPRESANT DRUGS MARKET, ($MILLION), GROWTH (%)2014-2022
  • TABLE 14: NORTH AMERICA ANTI REJECTION DRUGS / IMMUNOSUPPRESANT
  • TABLE 15: EUROPE ANTI REJECTION DRUGS / IMMUNOSUPPRESANT DRUGS MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 16: ASIA PACIFIC ANTI REJECTION DRUGS / IMMUNOSUPPRESANT DRUGS MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 17: LAMEA ANTI REJECTION DRUGS / IMMUNOSUPPRESANT DRUGS MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 18: WORLD CHEMOTHERAPY DRUGS MARKET, ($MILLION), GROWTH (%)2014-2022
  • TABLE 19: NORTH AMERICA CHEMOTHERAPY DRUGS MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 20: EUROPE CHEMOTHERAPY DRUGS MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 21: ASIA PACIFIC CHEMOTHERAPY DRUGS MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 22: LAMEA CHEMOTHERAPY DRUGS MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 23: WORLD TARGETED THERAPY MARKET, ($MILLION), GROWTH (%)2014-2022
  • TABLE 24: NORTH AMERICA TARGETED THERAPY MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 25: EUROPE TARGETED THERAPY MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 26: ASIA PACIFIC TARGETED THERAPY MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 27: LAMEA TARGETED THERAPY MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 28: WORLD IMMUNOGLOBULIN MARKET, ($MILLION), GROWTH (%)2014-2022
  • TABLE 29: NORTH AMERICA IMMUNOGLOBULIN MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 30: EUROPE IMMUNOGLOBULIN MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 31: ASIA PACIFIC IMMUNOGLOBULIN MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 32: LAMEA IMMUNOGLOBULIN MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 33: WORLD CORTICOSTEROIDS MARKET, ($MILLION), GROWTH (%)2014-2022
  • TABLE 34: NORTH AMERICA CORTICOSTEROIDS MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 35: EUROPE CORTICOSTEROIDS MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 36: ASIA PACIFIC CORTICOSTEROIDS MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 37: LAMEA CORTOCOSTEROIDS MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 38: NORTH AMERICA MARKET, ($MILLION), GROWTH (%)2014-2022
  • TABLE 39: U.S. LIVER DISEASE TREATMENT MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 40: MEXICO LIVER DISEASE TREATMENT MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 41: CANADA LIVER DISEASE TREATMENT MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 42: WORLD EUROPE MARKET, ($MILLION), GROWTH (%)2014-2022
  • TABLE 43: GERMANY LIVER DISEASE TREATMENT MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 44: UK LIVER DISEASE TREATMENT, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 45: ITALY LIVER DISEASE TREATMENT MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 46: FRANCE LIVER DISEASE TREATMENT MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 47: REST OF EUROPE LIVER DISEASE TREATMENT MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 48: ASIA PACIFIC MARKET, ($MILLION), GROWTH (%)2014-2022
  • TABLE 49: JAPAN LIVER DISEASE TREATMENT MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 50: CHINA LIVER DISEASE TREATMENT MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 51: INDIA LIVER DISEASE TREATMENT MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 52: REST OF APAC LIVER DISEASE TREATMENT MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 53: LAMEA MARKET, ($MILLION), GROWTH (%)2014-2022
  • TABLE 54: LATIN AMERICA LIVER DISEASE TREATMENT MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 55: MIDDLE EAST LIVER DISEASE TREATMENT MARKET, ($MILLION), GROWTH (%) 2014-2022
  • TABLE 56: AFRICA LIVER DISEASE TREATMENT MARKET, ($MILLION), GROWTH (%) 2014-2022

List of Figures

  • FIG. 1: TOP IMPACTING FACTORS
  • FIG. 2: TOP WINNING STRATEGIES IN THE LIVER DISEASE TREATMENT MARKET (20132016)
  • FIG. 3: TOP WINNING STRATEGIES (%) (20132016)
  • FIG. 4: TOP INVESTMENT POCKETS
  • FIG. 5: PORTERS FIVE FORCES ANALYSIS OF LIVER DISEASE TREATMENT MARKET
  • FIG. 6: MARKET SHARE ANALYSIS OF LIVER DISEASE TREATMENT MARKET, BY ANTIVIRAL DRUGS MARKET, 2015
  • FIG. 7: MARKET SHARE ANALYSIS OF LIVER DISEASE TREATMENT MARKET, BY ANTIREJECTION DRUGS / IMMUNOSUPPRESSANT DRUGS MARKET, 2015
  • FIG. 8: WORLD AGEING POPULATION EXPECTED GROWTH RATE, 2000, 2025 AND 2050
  • FIG. 9: DEVELOPMENT AND REGULATORY TIME PROFILE FOR NEW DRUG
  • FIG. 10: CLINICAL PHASE TRASITION PROBABILITY AND OVERALL CLINICAL APPROVAL SUCCESS RATE
  • FIG. 11: WORLD LIVER DISEASE TREATMENT MARKET BY TREATMENT TYPE, 2015 (PIE CHART OF GLOBAL NUMBERS BY TREATMENT TYPE)
  • FIG. 12: WORLD ANTIVIRAL DRUGS MARKET, YEAR ON YEAR GROWTH(%), 2015-2022
  • FIG. 13: WORLD VACCINES MARKET, YEAR ON YEAR GROWTH(%), 2015-2022
  • FIG. 14: WORLD ANTI REJECTION DRUGS / IMMUNOSUPPRESANT DRUGS, YEAR ON YEAR GROWTH(%), 2015-2022
  • FIG. 15: WORLD LIVER DISEASE TREATMENT MARKET, BY CHEMOTHERAPY DRUGS, YEAR ON YEAR GROWTH(%), 2015-2022
  • FIG. 16: WORLD TARGETED THERAPY MARKET, YEAR ON YEAR GROWTH(%), 2015-2022
  • FIG. 17: WORLD IMMUNOGLOBULIN MARKET , YEAR ON YEAR GROWTH(%), 2015-2022
  • FIG. 18: WORLD LIVER DISEASE TREATMENT MARKET, BY CORTICOSTEROIDS , YEAR ON YEAR GROWTH(%), 2015-2022
  • FIG. 19: WORLD LIVER DISEASE TREATMENT MARKET BY GEOGRAPHY, 2015(PIE CHART OF GLOBAL NUMBERS BY GEOGRAPHY)
  • FIG. 20: WORLD NORTH AMERICA MARKET, YEAR ON YEAR GROWTH(%), 2015-2022
  • FIG. 21: WORLD EUROPE MARKET, YEAR ON YEAR GROWTH(%), 2015-2022
  • FIG. 22: WORLD LIVER DISEASE TREATMENT MARKET, BY ASIA PACIFIC, YEAR ON YEAR GROWTH(%), 2015-2022
  • FIG. 23: WORLD LAMEA MARKET, YEAR ON YEAR GROWTH(%), 2015-2022
Back to Top